What does Hercules Capital do?

Hercules provides senior and junior debt, and sometimes equity-linked financing, to venture-backed and growth-stage companies—mainly in technology and life sciences.

How does the company generate returns for shareholders?

Returns come from interest and fees on loans and occasional equity gains from warrants or convertibles; dividends are paid from realised income and gains but can vary over time.

What are the main risks to be aware of?

Key risks include credit losses from portfolio companies, liquidity constraints, interest-rate sensitivity and concentration in certain sectors; these can affect dividend stability and capital value.

Is Hercules suitable for income investors?

It may suit income-oriented investors who accept higher credit and market risk, but suitability depends on individual goals, time horizon and risk tolerance—seek regulated advice for personal decisions.

Where can I find more information?

Read Hercules’s annual and quarterly filings (10-K/10-Q), dividend announcements and portfolio reports, and consider analyst notes and regulatory disclosures for deeper insight.

Hercules Capital (HTGC) Stock

Financing partner for technology and life science startups. Here's the price, business snapshot, and what's worth knowing about Hercules Capital in October 2026.

Hercules Capital Inc (HTGC) is a publicly traded business development company (BDC) that provides debt and selective equity financing to venture-backed and growth-stage companies, predominantly in technology and life sciences. It earns income from interest, fees and sometimes equity upside via warrants or convertibles, then aims to distribute a substantial portion of earnings as dividends. Investors should note the trade-off: BDCs can offer attractive yield but carry higher credit and liquidity risk than traditional banks, and dividend levels can fluctuate with realised gains, credit outcomes and regulatory limits. Hercules’s performance depends heavily on underwriting, portfolio diversity and the health of the sectors it lends to. Market capitalisation is about $3.22bn. This summary is educational only and not personalised advice; investors should review regulatory filings, understand BDC-specific risks and consider speaking to a regulated financial adviser to assess suitability.

≈

Why You’ll Want to Watch This Stock

📈

Venture-focused Lending

Lends to growth-stage tech and life-science companies, offering income potential; performance depends on portfolio credit quality and exits.

⚡

Income and Equity Upside

Generates interest income and occasional equity gains via warrants, but dividend levels can fluctuate with realised results and reserves.

🌍

Risk and Liquidity

Credit, liquidity and interest-rate sensitivity are central considerations; suitable for investors comfortable with BDC-specific volatility.

Frequently asked questions

Hercules Capital (HTGC) Stock

Financing partner for technology and life science startups. Here's the price, business snapshot, and what's worth knowing about Hercules Capital in October 2026.